859169-20-3

Basic information

• Product Name: 4-(ethoxycarbonylmethyl)phenylboronic acid, pinaco
• Synonyms: 4-(ethoxycarbonylmethyl)phenylboronic acid, pinaco;Ethyl 2-(4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate;Benzeneacetic acid, 4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, ethyl ester;Ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl);ETHYL 2-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ACETATE（WS202804）;(4-(2-ETHOXY-2-OXOETHYL)PHENYL)BORONIC ACID PINACOL ESTER
• CAS NO: 859169-20-3
• Molecular Formula: C₁₆H₂₃BO₄
• Molecular Weight: 290.165
• Mol File: 859169-20-3.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 377.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.06±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-(ethoxycarbonylmethyl)phenylboronic acid, pinaco(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(ethoxycarbonylmethyl)phenylboronic acid, pinaco(859169-20-3)
• EPA Substance Registry System: 4-(ethoxycarbonylmethyl)phenylboronic acid, pinaco(859169-20-3)

Safety Data

• Hazardous Substances Data: 859169-20-3(Hazardous Substances Data)

Usage

Uses

4-Ethoxycarbonylmethylphenylboronic acid, pinacol ester

Upstream product

• 5764-82-9 bromo(2-ethoxy-2-oxoethyl)zinc 
• 195062-61-4 4-chlorophenylboronic acid pinacol ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 15250-46-1 ethyl (4-iodophenyl)acetate 
• 73183-34-3 bis(pinacol)diborane 
• 797755-07-8 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid 
• 64-17-5 ethanol 
• 14062-25-0 Ethyl 4-bromophenylacetate 

Downstream Products

• 1204651-82-0 2-amino-1-ethyl-7-{4-[2-({[(2S)-1-ethyl-4,4-difluoropyrrolidin-2-yl]methyl}-amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-66-0 2-amino-1-ethyl-7-{4-[2-({[(2S,4R)-1-ethyl-4-fluoropyrrolidin-2-yl]methyl}-amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-88-6 2-amino-1-ethyl-N-methyl-7-{4-[2-({[4-(1-methylethyl)morpholin-3-yl]-methyl}amino)-2-oxoethyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide 
• 1204651-57-9 {4-[7-Amino-8-ethyl-6-(methyl carbamoyl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}acetic acid 
• 1204651-65-9 C₂₀H₁₉FN₄O₃ 
• 1204651-56-8 Ethyl {4-[7-amino-8-ethyl-6-(methylcarbamoyl)-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}acetate 
• 886363-28-6 2-(4-(1H-indol-5-yl)phenyl)acetic acid 

Relevant articles and documents

Coupling of Reformatsky Reagents with Aryl Chlorides Enabled by Ylide-Functionalized Phosphine Ligands

The coupling of aryl chlorides with Reformatsky reagents is a desirable strategy for the construction of α-aryl esters but has so far been substantially limited in the substrate scope due to many challenges posed by various possible side reactions. This limitation has now been overcome by the tailoring of ylide-functionalized phosphines to fit the requirements of Negishi couplings. Record-setting activities were achieved in palladium-catalyzed arylations of organozinc reagents with aryl electrophiles using a cyclohexyl-YPhos ligand bearing an ortho-tolyl-substituent in the backbone. This highly electron-rich, bulky ligand enables the use of aryl chlorides in room temperature couplings of Reformatsky reagents. The reaction scope covers diversely functionalized arylacetic and arylpropionic acid derivatives. Aryl bromides and chlorides can be converted selectively over triflate electrophiles, which permits consecutive coupling strategies.

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.

PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.